durvalumab

A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
 
Is this relevant?
Review
2017
Review
2017
The treatment of bladder cancer has evolved over time to encompass not only the traditional modalities of chemotherapy and… (More)
  • figure 1
  • table 1
  • table 1
  • table 1
  • table 2
Is this relevant?
2017
2017
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1… (More)
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PURPOSE To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand… (More)
Is this relevant?
2016
2016
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1) monotherapies have shown promising clinical activity… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2016
Review
2016
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2016
2016
PURPOSE To assess preliminary safety and efficacy results of the anti-programmed cell death ligand-1 (anti-PD-L1) durvalumab in… (More)
Is this relevant?